Drug Discovery News and Research

RSS
The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.
Hutchinson-Gilford Progeria Syndrome can be compared to normal aging, say scientists

Hutchinson-Gilford Progeria Syndrome can be compared to normal aging, say scientists

Biolin Scientific acquires the key patent protecting multi-hole, high-throughput ion channel screening

Biolin Scientific acquires the key patent protecting multi-hole, high-throughput ion channel screening

Removing volatile organic solvents from your 96-well microplates in minutes

Removing volatile organic solvents from your 96-well microplates in minutes

Heptares Therapeutics announces recipients of Malcolm Campbell Memorial Prize for 2015

Heptares Therapeutics announces recipients of Malcolm Campbell Memorial Prize for 2015

Heptares Therapeutics, AstraZeneca report significant progress in drug discovery collaboration

Heptares Therapeutics, AstraZeneca report significant progress in drug discovery collaboration

Penn researchers make breakthrough on novel anesthetics

Penn researchers make breakthrough on novel anesthetics

AMRI awarded NIH contract for drug development services

AMRI awarded NIH contract for drug development services

Abnormal attachment of sugar to BACE1 enzyme leads to formation of Aβ plaques in the brain

Abnormal attachment of sugar to BACE1 enzyme leads to formation of Aβ plaques in the brain

BellBrook Labs announces launch of new Transcreener UDP TR-FRET Assay

BellBrook Labs announces launch of new Transcreener UDP TR-FRET Assay

Crown's first European symposium to focus on use of Translational Platforms in oncology drug discovery

Crown's first European symposium to focus on use of Translational Platforms in oncology drug discovery

QDREC software may help find effective treatment for schistosomiasis

QDREC software may help find effective treatment for schistosomiasis

MGB Biopharma provides update on business performance for 2014

MGB Biopharma provides update on business performance for 2014

Precision NanoSystems, Arcturus Therapeutics partner to develop RNA medicines

Precision NanoSystems, Arcturus Therapeutics partner to develop RNA medicines

Crown Bioscience to double capacity of PRECOS facility, rename UK site

Crown Bioscience to double capacity of PRECOS facility, rename UK site

Proteomics market expected to experience continual growth

Proteomics market expected to experience continual growth

Porvair Sciences releases 2015 catalogue of tissue culture plastics and epigenetic consumables

Porvair Sciences releases 2015 catalogue of tissue culture plastics and epigenetic consumables

UTSA, UTHSCSA researchers to jointly develop next-generation breast cancer treatment drugs

UTSA, UTHSCSA researchers to jointly develop next-generation breast cancer treatment drugs

Penn, UGA scientists awarded new contract to develop genome database for microbial pathogens

Penn, UGA scientists awarded new contract to develop genome database for microbial pathogens

Pharmacology 2014 to showcase latest research on NHS care

Pharmacology 2014 to showcase latest research on NHS care

UB study creates new awareness for diabetics who are at risk for dehydration

UB study creates new awareness for diabetics who are at risk for dehydration

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.